Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
AJ Cooper, LV Sequist, JJ Lin - Nature Reviews Clinical Oncology, 2022 - nature.com
The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
M Canale, K Andrikou, I Priano, P Cravero, L Pasini… - Cancers, 2022 - mdpi.com
Simple Summary Non-Small-Cell Lung Cancer (NSCLC) is the primary cause of cancer-
related death worldwide. Patients carrying Epidermal Growth Factor Receptor (EGFR) …
related death worldwide. Patients carrying Epidermal Growth Factor Receptor (EGFR) …
[HTML][HTML] A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed …
Background While osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small …
tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small …
Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a …
RGP Gijtenbeek, RAM Damhuis… - The Lancet Regional …, 2023 - thelancet.com
Background Clinical guidelines advise osimertinib as preferred first line treatment for
advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer …
advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer …
TP53 co-mutations in advanced EGFR-mutated non–small cell lung cancer: Prognosis and therapeutic strategy for cancer therapy
S Liu, J Yu, H Zhang, J Liu - Frontiers in oncology, 2022 - frontiersin.org
Lung cancer is the leading cause of cancer-related deaths worldwide. As the most prevalent
molecular mutation subtypes in non-small cell lung cancer (NSCLC), EGFR-TKIs are …
molecular mutation subtypes in non-small cell lung cancer (NSCLC), EGFR-TKIs are …
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer
LT Huang, SL Zhang, CB Han, JT Ma - Lung Cancer, 2022 - Elsevier
Abstract Objective Exon 19 deletion (19del) is a sensitive mutation of epidermal growth
factor receptor (EGFR) observed in non-small cell lung cancer (NSCLC), and consists of a …
factor receptor (EGFR) observed in non-small cell lung cancer (NSCLC), and consists of a …
TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
X Le, C Molife, MS Leusch, MT Rizzo, PM Peterson… - Cancers, 2022 - mdpi.com
Simple Summary There is conflicting evidence on the impact of TP53 co-mutations on
survival in patients with EGFR-mutated advanced non-small cell lung cancer (aNSCLC) …
survival in patients with EGFR-mutated advanced non-small cell lung cancer (aNSCLC) …
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
H Sun, P Ren, Y Chen, L Lan, Z Yan, Y Yang, B Wang… - BMC cancer, 2023 - Springer
Background Non-small cell cancer (NSCLC) patients with concomitant epidermal growth
factor receptor (EGFR) and TP53 mutations have a poor prognosis with the treatment of …
factor receptor (EGFR) and TP53 mutations have a poor prognosis with the treatment of …
Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung …
Background: Osimertinib is a standard treatment option for epidermal growth factor receptor
(EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, osimertinib …
(EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, osimertinib …
Epidermal growth factor receptor compound and concomitant mutations: advances in precision treatment strategies
W Li, R Bai, H Guo, J Cui - Chinese Medical Journal, 2023 - mednexus.org
Epidermal growth factor receptor (EGFR) mutations are common oncogenic driver mutations
in patients with non-small cell lung cancer (NSCLC). The application of EGFR-tyrosine …
in patients with non-small cell lung cancer (NSCLC). The application of EGFR-tyrosine …